Sandoz Will Appeal Against US Enbrel Patent Setback

 
• By Aidan Fry
  
Signpost_2029
Sandoz could be barred from launching its Erelzi biosimilar etanercept in the US until 2029 following an adverse district court ruling • Source: Shutterstock

More from Biosimilars

More from Products